Last reviewed · How we verify
EXC 001
EXC 001 is a small molecule that targets the [insert target here, if known].
EXC 001 is a small molecule that targets the [insert target here, if known]. Used for Phase 2 for [insert indication here, if known].
At a glance
| Generic name | EXC 001 |
|---|---|
| Sponsor | Pfizer |
| Modality | Small molecule |
| Phase | Phase 2 |
Mechanism of action
Unfortunately, I do not have enough information to provide a deeper explanation of the mechanism.
Approved indications
- Phase 2 for [insert indication here, if known]
Common side effects
Key clinical trials
- Safety and Efficacy Study of Different Dose Levels of EXC 001 to Improve the Appearance of Scars in Subjects Undergoing Elective Abdominoplasty (PHASE2)
- Safety and Efficacy Study of EXC 001 to Improve the Appearance of Scars From Prior Breast Surgery (PHASE2)
- Safety and Efficacy of EXC 001 in Subjects Who Have Participated in Prior Studies of EXC 001 (PHASE2)
- Safety and Efficacy Study of EXC 001 to Improve the Appearance of Scars in Subjects Undergoing Elective Abdominoplasty (PHASE2)
- Safety and Efficacy Study of EXC 001 to Improve the Appearance of Scars From Prior Breast Surgery (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- EXC 001 CI brief — competitive landscape report
- EXC 001 updates RSS · CI watch RSS
- Pfizer portfolio CI